ISPC - iSpecimen - Stock Forecast

Coverage Stock analysts Price Targets & Ratings Chart Insider Trading

with an average price target of $3.35. This is a potential upside of $2.19 (188.79%) from yesterday's end of day stock price of $1.16.

iSpecimen's activity chart (see below) currently has 3 price targets and 2 ratings on display.

Stock Analyst Price Targets - Review

Analysts average stock forecasts to be materialized ratio is 100% with an average time for these price targets to be met of 363 days.

Most recent stock forecast was given by CONSTANTINE DAVIDES from BENCHMARK on 23-Sep-2022. First documented stock forecast 23-Nov-2021.

Best performing analysts who are covering ISPC - iSpecimen:

Constantine Davides

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date

Price targets met ratio

Average potential upside

Average Time (Days) For PT To Be Met

Performance score

Buy

$4.25

$-0.25 (-5.56%)

$12

2 years 10 months 21 days ago
(23-Sep-2022)

2/2 (100%)

$2.19 (106.31%)

363

Show more analysts

To gain access for the analyst/ stock price target chart please use a computer

What is ISPC (iSpecimen) average time for price targets to be met?

On average it took 363 days on average for the stock forecasts to be realized with a an average price target met ratio 100

Which analyst has the current highest performing score on ISPC (iSpecimen) with a proven track record?

CONSTANTINE DAVIDES

Which analyst has the most public recommendations on ISPC (iSpecimen)?

Constantine Davides works at JMP and has 6 price targets and 6 ratings on ISPC

Which analyst is the currently most bullish on ISPC (iSpecimen)?

Constantine Davides with highest potential upside - $-0.25

iSpecimen in the News

iSpecimen Inc. Announces Pricing of Approximately $1.75 Million Private Placement Priced At-the-Market

WOBURN, Mass., July 31, 2025 (GLOBE NEWSWIRE) — iSpecimen Inc. (Nasdaq: ISPC) (“iSpecimen” or the “Company”), an online global marketplace that connects scientists requiring biospecimens for medical research with a network of healthcare specimen providers, today announced that it entered into a securities purchase agreement with accredited investors for aggregate gross proceeds of approximately $1.75...

To continue looking at which analysts cover the stock please register to the basic or advanced membership

What is AnaChart?